Abstract
Introduction
It is estimated that North Americans have an approximately 40% risk of developing cancer in their lifetimes [1, 2] . With many cancers, early detection and timely treatment with existing therapies can successfully reduce morbidity and mortality, such that a little less than half of patients diagnosed with cancer will actually die of the disease [1] . Depending on the type and severity of the cancer, current therapeutic options include surgery, radiation therapy (RT), and systemic therapies such as cytotoxic chemotherapy and/or hormonal therapy [3, 4] . More [6, 7] and targeting of the epidermal growth factor (EGFR) with Iressa ® (gefitinib; lung cancer) [8] .
Despite these promising advances, the majority (if not all) of these therapies fail in the metastatic setting. For example, even after complete remission in response to therapy, less than 20% of patients with
metastatic breast cancer will remain disease-free for more than 5 years [9] . Therefore 
The metastatic process
Metastasis is a sequential, multi-step process that requires cancer cells to escape from the primary tumour, intravasate into the circulation or lymphatic system, migrate through the body, adhere at a secondary site, extravasate from the circulation and into the secondary tissue, form micrometastases, develop a blood supply, and finally form macroscopic, clinically relevant metastases (Fig. 1) [10, 11] .
Metastatic inefficiency
Based on the complexity of the metastatic process, it seems unlikely that all cancer cells would be able to successfully complete all the steps necessary to form clinically relevant metastases. Indeed, it is known that metastasis is a highly inefficient process, and interestingly, that not all the steps of the metastatic process are equally inefficient [10, 12, 13] . Previous studies by Luzzi et al. (1998) [10, 11] . It was originally believed that many metastases could be explained purely by circulatory patterns [14] . According to this mechanical hypothesis, since cancer cells are much larger than blood cells, cancer cells would be forced to arrest in the capillary bed of the first organ they encounter in the circulation, and thus form metastases wherever they are stopped [10, 14] [16] . In a meta-analysis of published autopsy study data [17] [29, 30] . Given the developmental origin of EMT, it is interesting but not surprising that many of these molecules have also been associated with stem cell maintenance [22] 
Epithelial-mesenchymal transition (EMT)

Defining the CSC
Given the intense research interest in the CSC hypothesis, it is important at this stage to more clearly define what makes a cancer cell a 'CSC' so that researchers working in different model
Identifying and isolating CSCs
In order to study CSCs 
The metastatic niche
Normal stem cells require a specific niche or microenvironment in order to grow and survive [57] [58] [59] [18, 19, 48, 68, 69, 72-74, 76-79, 81, 91, 92, 96, 97, 101, 102] . [65] . [66] . [31, 57, 59, 60, 67, 68] [52] . [18] [76] . [80, [83] [84] [85] . This drug resistance could be an inherent feature of CSCs, and could help explain the high level of drug resistance in metastatic disease [52, 81] .
Interestingly, when LOX was inhibited (using ␤-aminoproprionitrile [BAPN] or an antibody targeting LOX), metastasis was eliminated in mice, but there was no effect on the primary tumour. This suggests that hypoxic environments and the induced expression of LOX and HIF are important in the metastatic setting. Normal stem cells also do well in hypoxic environments, typically maintaining an undifferentiated state that is important to preservation of the stem cell pool
There has been some controversy over whether or not CSCs require specific niches to grow. However, in leukaemia, studies have shown that leukaemia stem cells actually occupy a similar region as normal haematopoietic stem cells (the perioendosteal region), suggesting that CSCs may in fact require a niche to protect and maintain the tumour initiating/tumour sustaining CSCs [57]. In the situation of metastasis, we might consider that the tumour microenvironment in a secondary organ is in fact a 'metastatic niche'. Initially, it was believed that the microenvironment where a metastatic cell ended up either passively supported tumour development and facilitated tumour formation, or it did not support growth, and no tumour was able to form. As discussed above, there is now evidence to suggest that the tumour microenvironment actively contributes to the growth and invasion of metastatic tumours, and that non-CSCs may actually contribute to the creation of the CSC niche
The SDF-1/CXCR4 axis
Another similarity between metastatic cells and stem cells is their use of chemokine pathways for migration. The chemokine SDF-1 is believed to play a critical role in stem cell migration in cooperation with its receptor CXCR4 [19]. SDF-1 is an ideal candidate for aiding in metastasis because its major biological effects are related to the ability of this chemokine to induce motility, chemotactic responses, adhesion, secretion of MMPs and secretion of angiopoietic factors such as VEGF in cells that express CXCR4. SDF-1 also increases adhesion of cells to VCAM-1, fibronectin and fibrinogen by activating/modulating the function of several cell surface integrins
Resistance to apoptosis and protection from cellular insult
Resistance to apoptosis is another key property shared by both normal stem cells and highly malignant tumour cells. Stem cells can resist apoptosis by a number of mechanisms, including via TGF-␤ signalling or activation of the Hedgehog (HH) pathway
Finally, stem cells are also thought to be more resistant to DNA damaging agents than differentiated cells because of their ability to undergo asynchronous DNA synthesis and their enhanced capacity for DNA repair. During asynchronous DNA synthesis, the parental 'immortal' DNA strand always segregates with the new stem cell rather than with the differentiating progeny, thus helping to protect the stem cell population from DNA damage [86] [87] [88] [89] [90] . Similarly, CSCs are believed to be resistant to radiation therapy by preferentially upregulating their DNA proofreading mechanisms in order to avoid cellular death due to DNA damage [91] [92] . Studies have shown that treating a tumour with radiation can deplete the non-CSC population and increase the CSC population by 3-5 fold, thus rendering the tumour even more aggressive and resistant to treatment [92] . It is also possible that CSCs may tend to be located in the hypoxic regions of tumours, which would affect their sensitivity to radiation via the oxygen enhancement ratio. It is more likely that radioresistance is a general property of CSCs, due to their ability to more efficiently repair their DNA than non-CSCs [93] .
Origin of the CSC: normal stem cell gone bad?
Given the many parallels between stem cells and metastatic cancer cells, one of the most elusive and highly debated research questions surrounding the CSC hypothesis is regarding the definitive cellular origin of the CSC [45, 53] [73] . In brain cancer, intracranial glioblastoma and medulloblastoma xenografts treated with another CXCR4 antagonist (AMD3100) showed reduced cell growth and increased tumour cell apoptosis [74] . Furthermore, Jin et al. (2006) [107] . However, the large body of work from Joan Massagué's group (reviewed in [108] ) and additional 'CSC' subpopulation gene expression studies by Shipitsin et al. (2007) [47] 
